Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | GBA1 | P04062 | 2/20 | 0.59 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.55 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 8/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.54 |
| ▸ | RELA | Q04206 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 7/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4683620 | 0.86 | MEN1 (0.59) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL29684206 | 0.85 | HDAC8 (0.57) | MEN1KMT2AGBA1KCNK3KCNK9 | |
| SCHEMBL3914463 | 0.85 | NAMPT (0.63) | MEN1KMT2ARAB9ANPC1GBA1 | |
| SCHEMBL20389106 | 0.84 | MEN1 (0.55) | MEN1KMT2ARAB9ANPC1GBA1 | |
| SCHEMBL29952373 | 0.81 | GBA1 (0.53) | MEN1KMT2ARAB9ANPC1GBA1 | |
| SCHEMBL10406072 | 0.80 | KMT2A (0.66) | MEN1KMT2ARAB9AKCNK3SMN1; SMN2 | |
| SCHEMBL418428 | 0.79 | — | — | |
| Benzene SCHEMBL29129490 | 0.79 | GAA (0.58) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL18825696 | 0.79 | NAMPT (0.50) | MEN1KMT2ARAB9ANPC1GBA1 | |
| SCHEMBL20379964 | 0.79 | MAPT (0.63) | MEN1KMT2ARAB9ANPC1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035386-A1 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASES | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | claimed |
| WO-2007149031-A1 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | claimed |
| US-5541299-A | Process for the preparation of dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1996-07-30 | — | — | US | claimed |
| EP-3284481-B1 | CELL DEATH INDUCING AGENT FOR CELLS HAVING BRAF GENE MUTATION, AGENT FOR INHIBITING PROLIFERATION OF SAID CELLS AND PHARMACEUTICAL COMPOSITION FOR TREATING PATIENT SUFFERING FROM EFFECTS OF ABNORMAL PROLIFERATION OF SAID CELLS | NITTO DENKO CORP (JP) | 2024-05-15 | — | — | EP | disclosed |
| CN-116271056-A | Cell death inducing agent for cell having BRAF gene mutation, proliferation inhibiting agent for the cell, and pharmaceutical composition for treating disease caused by abnormal proliferation of the cell | 日东电工株式会社 | 2023-06-23 | — | — | CN | disclosed |
| EP-4117703-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CORONAVIRUS INFECTION | Constant Therapeutics LLC (US) | 2023-01-18 | — | — | EP | disclosed |
| WO-2021183863-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CORONAVIRUS INFECTION | CONSTANT THERAPEUTICS LLC (US) | 2021-09-16 | — | — | WO | disclosed |
| US-10570396-B2 | Cell death inducing agent for cells having BRAF gene mutation, growth suppressing agent for same cells and pharmaceutical composition for therapy of diseases caused by growth defect of same cells | NITTO DENKO CORPORATION (JP) | 2020-02-25 | — | — | US | disclosed |
| EP-3373951-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF EPIDERMOLYSIS BULLOSA | Tarix Pharmaceuticals Ltd. (US) | 2018-09-19 | — | — | EP | disclosed |
| US-20180135058-A1 | CELL DEATH INDUCING AGENT FOR CELLS HAVING BRAF GENE MUTATION, GROWTH SUPPRESSING AGENT FOR SAME CELLS AND PHARMACEUTICAL COMPOSITION FOR THERAPY OF DISEASES CAUSED BY GROWTH DEFECT OF SAME CELLS | NITTO DENKO CORPORATION (JP) | 2018-05-17 | — | — | US | disclosed |
| CN-105949161-B | A kind of preparation method of 3- aromatic thiohydroxies chromocor compound | 温州大学 | 2018-05-15 | — | — | CN | disclosed |
| WO-2013090833-A1 | ANGIOTENSINS FOR TREATMENT OF FIBROSIS | TARIX PHARMACEUTICALS LTD. (US) | 2013-06-20 | — | — | WO | disclosed |
| US-7838676-B2 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| US-5578711-A | Process for the preparation of dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1996-11-26 | — | — | US | disclosed |
| US-5541299-A | Process for the preparation of dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1996-07-30 | — | — | US | disclosed |
| US-5502171-A | Process for the preparation of dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1996-03-26 | — | — | US | disclosed |
| US-4199360-A | DISSOLVING METHINE DYE IN PRESENCE OF RED SHIFT COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 1980-04-22 | — | — | US | disclosed |
| US-4138266-A | SULFO-SUBSTITUTED CYANINE AND RED SHIFT TRIAZOLE DYES | FUJI PHOTO FILM CO., LTD. (JP) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | MKI67, CCNB1, RB1 | MEN1 2752/4885KMT2A 3463/4885RAB9A 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.